Risperdal News and Research

RSS

Warning about use of psychiatric drugs with the elderly

Health officials in the U.S. are warning doctors that prescribing certain psychiatric drugs to elderly people suffering from dementia can increase their risk of death.

17 Jun 2008

Antipsychotic drugs get FDA label changes

The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia.

16 Jun 2008

Antipsychotic drugs dangerous for the elderly

A Canadian study has found that prescribing antipsychotic drugs for elderly people may be dangerous.

27 May 2008

Study suggests Risperidone long-acting injection combined with standard treatment helped delay time to relapse in patients with bipolar disorder

Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

4 Feb 2008

Placebo better than antipsychotic drugs for treating aggression in the intellectually disabled

Antipsychotic drugs which are commonly used to treat aggression in people who are intellectually disabled have been revealed to be ineffective.

6 Jan 2008

Long term use of Ritalin ineffective and may stunt childrens growth

The latest research from the U.S. says the long-term use of drugs such as Ritalin and Concerta for the treatment of children with Attention Deficit Hyperactivity Disorder (ADHD) is not effective.

13 Nov 2007

Risperdal approved for psychiatric conditions in children and adolescents

The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.

24 Aug 2007

Antipsychotic drug Risperdal approved for use in children

The Food and Drug Administration (FDA) in the U.S. has given approval for the antipsychotic drug Risperdal to be used to treat schizophrenia and bipolar disorder in children and teenagers.

23 Aug 2007

Risperidone may help people with autism

Risperidone, a drug used to control schizophrenia symptoms, may also help treat behaviors found in autism spectrum disorder, according to a new review of studies.

30 Jan 2007

Schizophrenia treatment with older, generic antipsychotics cheaper, as effective as treatment with newer drugs

Treating schizophrenia patients with older, less expensive antipsychotic drugs reduces overall treatment costs by up to 30% and produces no increase in side effects or decrease in effectiveness compared with newer, brand-name medications.

2 Dec 2006

Schizophrenia drug to be used to treat autism

A drug normally used to treat schizophrenia has been given approval by the U.S. the Food and Drug Administration for use in treating the symptoms of autism in children and adolescents.

9 Oct 2006

FDA approves Risperdal to treat irritability associated with autism

The U.S. Food and Drug Administration (FDA) has approved Risperdal (risperidone) orally disintegrating tablets, an adult antipsychotic drug, for the symptomatic treatment of irritability in autistic children and adolescents.

8 Oct 2006

Elderly as much at risk with old mental health drugs as new ones

Researchers at the Brigham and Women's Hospital in Boston are saying that many of the older drugs designed to treat mental problems such as delirium, agitation and psychosis may be even more hazardous to the elderly than newer medicines that now carry U.S. government warnings.

2 Dec 2005

FDA issues public health advisory for antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.”

12 Apr 2005

FDA wants warnings put on antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.”

11 Apr 2005

Metabolic side effects of antipsychotics are known, but rarely monitored

Psychiatrists are doing a “modest” job of monitoring for weight gain, diabetes and other metabolic problems that may result from use of the newer antipsychotics for schizophrenia, researchers say.

5 Apr 2005

Janssen Pharmaceutica has sent a letter to health care providers to clarify the risks involved with the use of RISPERDAL®

Janssen Pharmaceutica, the maker of RISPERDAL® (risperidone), the most frequently prescribed antipsychotic medication in the U.S., has sent a letter to health care providers to clarify the risks involved with the use of RISPERDAL®.

26 Jul 2004

Coronary stent drives Johnson & Johnson to record profits

Johnson & Johnson today announced sales for the first quarter of $11.6 billion, an increase of 17.7% over the prior year. The increase represented operational growth of 12.3% and a currency impact of 5.4%. Domestic sales were up 15.1%, while international sales increased 21.8%, including operational growth of 7.8% and a positive currency impact of 14.0%.

13 Apr 2004